RxDoctor Payments Data

Molly Furey, PA

Physician Assistant · Charlotte, NCNPI 1295248052

Payments from drug & device makers

$5,681in general payments, 2019–2025

Across 276 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AstraZeneca$824
  • AbbVie$604
  • Novo Nordisk$483
  • Pfizer$367
  • Amgen$300
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,681 in reported general payments places this provider in the 90th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$86,713
Medicare patients
314
Services billed
1,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$32,455
EliquisApixaban32$29,053
FarxigaDapagliflozin Propanediol27$28,559
MounjaroTirzepatide22$26,444
WegovySemaglutide11$19,451
XareltoRivaroxaban18$16,359
MyrbetriqMirabegron13$5,735
Levothyroxine Sodium187$2,521
Mirtazapine64$2,055
SynthroidLevothyroxine Sodium22$1,727
Omeprazole122$1,544
Buspirone Hcl72$1,447
Amlodipine Besylate189$1,421
Atorvastatin Calcium126$1,407
Dapsone11$1,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$483$51,90635 claims
PfizerEliquis$367$29,05332 claims
AstraZenecaFarxiga$824$28,55927 claims
Lilly USA, LLCMounjaro$1,031$26,44422 claims
Johnson & JohnsonXarelto$196$16,35918 claims
Astellas Pharma US IncMyrbetriq$194$5,73513 claims
AbbVieSynthroid$604$1,72722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →